Skip to main content
SpringerLink
Log in

Osteoonkologie: Knochenmetastasen und Tumortherapie-induzierte Osteoporose

  • Living reference work entry
  • First Online:
Kompendium Internistische Onkologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 44 Accesses

Zusammenfassung

Die Osteoonkologie untersucht die Wechselwirkung zwischen Tumorerkrankungen, Tumortherapie und dem Knochen und beschäftigt sich mit therapeutischen Möglichkeiten, metabolische und metastatische Skeletterkrankungen zu vermeiden oder zu behandeln. Die Osteoonkologie hat 3 Schwerpunkte: Behandlung von Knochenmetastasen und Knochenschmerzen, Prävention und Behandlung der Tumortherapie-induzierten Osteoporose und Prävention von ossären Metastasen. Die Tumortherapie-induzierte Osteoporose im Rahmen eines therapiebedingten Hypogonadismus durch endokrine oder zytotoxische Substanzen, ist eine Langzeitkomplikation, die in den letzten Jahren zu vermehrter Aufmerksamkeit geführt hat. Onkologen sollten sich mit den Grundlagen der Knochengesundheit auskennen und therapeutische Empfehlungen umsetzen. Daher sollten diejenigen, die für diese Langzeitkomplikation verantwortlich sind, sich weiterbilden, um entscheiden zu können, wann osteoprotektive Medikamente zur Vermeidung einer Fraktur eingesetzt werden sollten und welche Basismaßnahmen zum Erhalt der Knochengesundheit vermittelt werden müssen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Literatur

  • Barrett-Lee P, Casbard A, Abraham J et al (2014) Oral ibandronic acid vs. intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomized, open label, non-inferiority phase 3 trial. Lancet Oncolc 15:114–122

    Article  CAS  Google Scholar 

  • Body JJ, Diel IJ, Bell R et al (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111:306–312

    Article  CAS  PubMed  Google Scholar 

  • Body JJ, Diel IJ, Lichinitser MR et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399–1405

    Article  PubMed  Google Scholar 

  • Brufsky AM, Harker WG, Beck JT et al (2012) Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 118:1192–1201

    Article  CAS  PubMed  Google Scholar 

  • Buckwalterr JA, Brandser ER (1997) Metastatic disease of the skeleton. Am Fam Physician 55:1761

    Google Scholar 

  • Casey R, Gesztesi Z, Rochford J (2010) Long term zoledronic acid during androgen blockade for prostate cancer. Can J Urol 17:5170–5177

    PubMed  Google Scholar 

  • Chow E, Harris K, Fan G et al (2007) Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 25(11):1423–1436

    Article  PubMed  Google Scholar 

  • Chow E, van der Linden YM, Roos D et al (2014) Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol 15:164–171

    Article  PubMed  Google Scholar 

  • Cleeland CS, Body JJ, Stopeck et al (2013) Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 119:832–838

    Article  CAS  PubMed  Google Scholar 

  • Coleman R, Body JJ, Aapro M et al (2014) Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 3:124–137

    Article  Google Scholar 

  • Coleman R, de Boer R, Eidtmann H et al (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 24:398–405

    Article  CAS  PubMed  Google Scholar 

  • Coleman R, Finkelstein D, Barrios C, et al on behalf of the D-CARE Global Investigators (2018) Adjuvant denosumab in early breast cancer: first results from the international multicenter randomized phase III placebo controlled D-CARE study. J Clin Oncol 36(suppl):abstr 501

    Article  Google Scholar 

  • Coleman R, Powles T, Paterson A et al (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patients data from randomized trials. Lancet 386:1353–1361

    Article  Google Scholar 

  • Coleman RE (2006) Clinical features of metastastic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(Suppl 20):6243s–6249s

    Article  PubMed  Google Scholar 

  • Coleman RE, Banks LM, Girgis SI et al (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8:119–127

    Article  CAS  PubMed  Google Scholar 

  • Coleman RE, Marshall H, Cameron D et al (2011) Breast cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396–1405

    Article  CAS  PubMed  Google Scholar 

  • Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6:163–174

    CAS  PubMed  Google Scholar 

  • Currie GL, Delaney A, Bennett MI et al (2013) Animal models of bone cancer pain: systematic review and meta-analyses. Pain 154:917–926

    Article  PubMed  Google Scholar 

  • Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET (2005) Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 65(18):8274–8285

    Article  CAS  PubMed  Google Scholar 

  • Damron TA, Morgan H, Prakash D et al (2003) Critical evaluation of Mirels’ rating system for impending pathologic fractures. Clin Orthop Relat Res 415 Suppl:S201–S207

    Article  Google Scholar 

  • Daubiné F, Le Gall C, Gasser J, Green J, Clézardin P (2007) Antitumor effects of clinical dosis regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 99:322–300

    Article  PubMed  CAS  Google Scholar 

  • De Felice F, Piccioli A, Musio D, Tombolini V (2017) The role of radiotherapy in bone metastases management. Oncotarget 15:25691–25699

    Article  Google Scholar 

  • Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29:117–129

    Article  CAS  PubMed  Google Scholar 

  • Diel IJ, Body JJ, Lichinitser MR et al (2004) Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40:1704–1712

    Article  CAS  PubMed  Google Scholar 

  • Diel IJ, Jaschke A, Solomayer EF et al (2008) Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow – a long term follow-up. Ann Oncol 19:2007–2011

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Diel IJ, Solomayer EF, Costa SD et al (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357–363

    Article  CAS  PubMed  Google Scholar 

  • Domchek SM, Younger J, Finkelstein DM et al (2000) Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 89:363–368

    Article  CAS  PubMed  Google Scholar 

  • Dunning EC, Butler JS, Morris S (2012) Complications in the management of metastatic spinal disease. World J Orthop 3(8):114–121

    Article  PubMed  PubMed Central  Google Scholar 

  • Eastell R, Adams JE, Coleman RE et al (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26:1051–1057

    Article  CAS  PubMed  Google Scholar 

  • Eidtmann H, de Boer R, Bundred N et al (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-months results of the ZO-FAST-study. Ann Oncol 21:2188–2194

    Article  CAS  PubMed  Google Scholar 

  • Ellis GK, Bone HG, Chlebowski R et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for non-metastatic breast cancer. J Clin Oncol 26:4875–4882

    Article  CAS  PubMed  Google Scholar 

  • Evans AR, Bottros J, Grant W et al (2008) Mirels‘ rating for humerus lesions is both reproducible and valid. Clin Orthop Relat Res 466(6):1279–1284

    Article  PubMed  PubMed Central  Google Scholar 

  • Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652–1662

    Article  CAS  PubMed  Google Scholar 

  • Fisher CG, DiPaola CP, Ryken TC et al (2010) A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine 35(22):E1221–E1229. (Review)

    Article  PubMed  Google Scholar 

  • Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9.768):813–822

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ford J, Cummins E, Sharma P et al (2012) Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumors. Health Technol Assess 17(29)

    Google Scholar 

  • Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al; Austrian Breast and Colorectal Cancer Study Group (ABCSG) (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840–849

    Article  CAS  PubMed  Google Scholar 

  • Gnant M, Mlineritsch B, Schippinger W et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679–691

    Article  CAS  PubMed  Google Scholar 

  • Gnant M, Pfeiler G, Dubsky PC et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386:433–443

    Article  CAS  PubMed  Google Scholar 

  • Gnant M, Pfeiler G, Stegner D, et al on behalf of the ABCSG (2018) Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3425 postmenopausal patients in the ABCSG-18 trial. J Clin Oncol 36. (suppl; abstr 500)

    Google Scholar 

  • Goblirsch MJ, Zwolak PP, Clohisy DR (2006) Biology of cancer pain. Clin Cancer Res 12(20 Suppl):6231s–6235s

    Article  CAS  PubMed  Google Scholar 

  • Goetz MP, Callstrom MR, Charboneau JW et al (2004) Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol 22(2):300–306

    Article  PubMed  Google Scholar 

  • Good JS, Harrington KJ (2013) The hallmarks of cancer and the radiation oncologist: updating the 5Rs of radiobiology. Clin Cancer 25:569–577

    CAS  Google Scholar 

  • Goss PE, Hershman DL, Cheung AM et al (2014) Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. Lancet Oncol 15:474–482

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Greenspan SL, Nelson JB, Trump DL, Resnick NM (2007) Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 146:416–424

    Article  PubMed  Google Scholar 

  • Guise TA, Mohammad KS, Clines G et al (2006) Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12(20 Pt 2):6.213s–6.216

    Google Scholar 

  • Hadji P, Aapro MS, Body JJ et al (2017) Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 7:1–12

    Article  PubMed  PubMed Central  Google Scholar 

  • Hadji P, Gnant M, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Guise TA, Lipton A, Aapro MS (2012) Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? Cancer Treat Rev 38:798–806

    Article  CAS  PubMed  Google Scholar 

  • Hall CL, Kang S, MacDougald OA, Keller ET (2006) Role of Wnts in prostate cancer bone metastases. J Cell Biochem 97:661–672

    Article  CAS  PubMed  Google Scholar 

  • Harrington KD (1986) Impending pathologic fractures from metastatic malignancy: evaluation and management. Instr Course Lect 35:357–381

    CAS  PubMed  Google Scholar 

  • Hartsell WF, Scott CB, Bruner DW et al (2005) Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 97(11):798–804

    Article  PubMed  Google Scholar 

  • Heini PF, Walchli B, Berlemann U (2000) Percutaneous transpedicular vertebroplasty with PMMA: operative technique and early results. A prospective study for the treatment of osteoporotic compression fractures. Eur Spine J 9(5):445–450

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Himelstein A, Foster JC, Khatcheressian JL et al (2017) Effect of longer-intervall vs standard dosing of zoledronic acid on skeletal events in partients with bone metastases: a randomized clinical trial. JAMA 317:48–58

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hofbauer LC, Rachner TD, Coleman RE, Jakob F (2014) Endocrine aspects of bone metastases. Lancet Diabetes Endocrinol 2:500–512

    Article  CAS  PubMed  Google Scholar 

  • Horlemann J. DGS-PraxisLeitlinie Tumorschmerz. http://www.DGS-PraxisLeitlinien.de

  • Hortobagyi GN, Theriault RL, Lipton A et al (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16:2038–2044

    Article  CAS  PubMed  Google Scholar 

  • Hortobagyi GN, Van Poznak C, Harker WG et al (2017) Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastastic to the bone: The OPTIMIZE-2 randomized clinical trial. JAMA Oncol

    Google Scholar 

  • Hoskin P, Sundar S, Reczko K et al (2015) A multicenter randomized trial of ibandronate compared with single-dose radiotherapy for localized metastatic bone pain in prostate cancer. J Natl Cancer Inst 107:pii: djv197. https://doi.org/10.1093/jnci/djv197

    Article  CAS  Google Scholar 

  • Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62

    Article  CAS  PubMed  Google Scholar 

  • Israeli RS, Rosenberg SJ, Saltzstein DR et al (2007) The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 5:271–277

    Article  CAS  PubMed  Google Scholar 

  • Jagdev SP, Coleman RE, Shipman CM et al (2001) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells; evidence for synergy with paclitaxel. Br J Cancer 84:1126–1134

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jehn CF, Diel IJ, Overkamp F et al (2016) Management of metastatic bone disease algorithms for diagnostics and treatment. Anticancer Res 36(6):2631–2637

    CAS  PubMed  Google Scholar 

  • Kohno N, Aogi K, Minami H et al (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314–3321

    Article  CAS  PubMed  Google Scholar 

  • Lassemillante AC, Doi SA, Hooper JD et al (2015) Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy. Endocrine 50:344–54

    Article  PubMed  CAS  Google Scholar 

  • Leithner A, Friesenbichler J, Andreou D et al (2012) Bone metastases treatment strategies. Orthopaede 41(10):863–871

    Article  CAS  Google Scholar 

  • Leithner A, Maurer-Ertl W, Windhager R (2009) Biopsy of bone and soft tissue tumours: hints and hazards. Recent Results Cancer Res 179:3–10. Review

    Article  PubMed  Google Scholar 

  • Lester JE, Dodwell D, Purohit OP et al (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14:6336–6342

    Article  CAS  PubMed  Google Scholar 

  • Liao J, McCauley LK (2006) Skeletal metastasis: established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev 25:559–571

    Article  CAS  PubMed  Google Scholar 

  • Libson E, Bloom RA, Husband JE et al (1987) Metastatic tumours of bones of the hand and foot. A comparative review and report. Skeletal Radiol 16:387

    Article  CAS  PubMed  Google Scholar 

  • Lipton A, Fizazi K, Stopeck AT et al (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082–3092

    Article  CAS  PubMed  Google Scholar 

  • Llombart A, Frassoldati A, Paija O et al (2012) Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 12:40–48

    Article  CAS  PubMed  Google Scholar 

  • Lomax AJ, Yee Yap S, White K et al (2013b) Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: the BATMAN Trial. J Bone Oncol 2:145–153

    Article  PubMed  PubMed Central  Google Scholar 

  • Lomax ME, Folkes LK, O‘Neill P (2013a) Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. Clin Oncol 25:578–585

    Article  CAS  Google Scholar 

  • Lozano-Ondoua AN, Symons-Ligouri AM, Vanderah TW (2013) Cancer-induced bone pain: mechanisms and models. Neurosci Lett:52–59

    Google Scholar 

  • Luger NM, March DB, Sevcik MA, Manthy PW (2005) Bone cancer pain. From model to mechanisms to therapy. J Pain Symptom Manage 29:S32–S46

    Article  CAS  PubMed  Google Scholar 

  • Lumachi F (2008) Medical treatment of malignancy-associated hypercalcemia. Curr Med Chem 15:415–421

    Article  CAS  PubMed  Google Scholar 

  • Lutz S, Berk L, Chang E et al (2015) Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 79:965–976

    Article  Google Scholar 

  • Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C (1999) Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 161:1219–1222

    Article  CAS  PubMed  Google Scholar 

  • Mantyh P (2013) Bone cancer pain. Pain 154:S54–S62

    Article  PubMed  Google Scholar 

  • Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP (2002) Molecular mechanisms of cancer pain. Nat Rev Cancer 2:201–209

    Article  CAS  PubMed  Google Scholar 

  • Martin M, Bell R, Bourgeois H et al (2012) Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res 18:4841–4849

    Article  CAS  PubMed  Google Scholar 

  • Michaelson MD, Kaufman DS, Lee H et al (2007) Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25:1038–1042

    Article  CAS  PubMed  Google Scholar 

  • Mirels H (1989) Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathologic fractures. Clin Ortop Relat Res 249:256–264

    Google Scholar 

  • Mirels H (2003) The classic: metastatic disease in long bones a proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res 415(415 Suppl):S4–S13

    Article  Google Scholar 

  • Oefelein MG, Ricchiuti V, Conrad W, Resnick MI (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168:1005–1007

    Article  PubMed  Google Scholar 

  • Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, Richhariya A, Dodge T, Wolff GG, Balakumaran A, Edelsberg J (2013) Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer 21(12):3279–3286. https://doi.org/10.1007/s00520-013-1887-3. Epub 2013 Jul 25. PMID: 23884473

  • Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223

    Article  CAS  PubMed  Google Scholar 

  • Patchell RA, Tibbs PA, Regine WF et al (2005) Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 366:643–648

    Article  PubMed  Google Scholar 

  • Paterson AHG, Anderson SJ, Lembersky BC et al (2012) Oral clodronate for adjuvant treatment of operable breast cancer (NSABP-project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 13:734–742

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ, Shaughnessy JD Jr (2009) The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 113:517–525

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, Bennett RC, Martin TJ (1991) Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 51:3059–3061

    CAS  PubMed  Google Scholar 

  • Powles TJ, Paterson AHG, Kanis JA et al (2002) Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20:3219–3224

    Article  CAS  PubMed  Google Scholar 

  • Rabaglio M, Sun Z, Price KN et al (2009) Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 19–8 trial. Ann Oncol 20:1489–1498

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rachner TD, Coleman R, Hadji P, Hofbauer LC (2018) Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol. in Press

    Google Scholar 

  • Rachner TD, Wimberger P, Hofbauer LC (2015) Prospects of adjuvant RANKL inhibition in breast cancer? Cell Death Dis 19(6):e1982

    Article  CAS  Google Scholar 

  • Rades D, Huttenlocher S, Bajrovic A et al (2011) Surgery followed by radiotherapy versus radiotherapy alone for metastatic spinal cord compression from unfavorable tumors. Int J Radiat Oncol Biol Phys 81:e861–e868

    Article  PubMed  Google Scholar 

  • Rodan GA, Fleisch H (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97:2692–2696

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates. Clin Cancer Res 12(20 Suppl):6222s–6230s

    Article  CAS  PubMed  Google Scholar 

  • Rogers MJ, Frith JC, Luckman SP et al (1999) Molecular mechanism of action of bisphosphonates. Bone 24:73S–79S

    Article  CAS  PubMed  Google Scholar 

  • Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655–1664

    Article  CAS  PubMed  Google Scholar 

  • Roqué M, Martinez MJ, Alonso P et al. (2003) Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev (4):CD003347. Review. Update in: (2011) Cochrane Database Syst Rev (7):CD003347

    Google Scholar 

  • Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735–1744

    Article  CAS  PubMed  Google Scholar 

  • S3-Leitlinie Supportive Therapien bei onkologischen PatientInnen. April 2017. AWMF-Registernummer: 032/054OL (Seiten 300-306)

    Google Scholar 

  • Saarto T, Blomqvist C, Virkkunen P, Elomaa I (2001) Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19:10–17

    Article  CAS  PubMed  Google Scholar 

  • Sartor O, Coleman R, Nilsson S et al (2014) Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 15:738–746

    Article  CAS  PubMed  Google Scholar 

  • Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164

    Article  CAS  PubMed  Google Scholar 

  • Smith I, Yardley D, Burris H et al (2017) Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: final results of the randomized phase III Femara Versus Anastrozole Clinical Evaluation (FACE) trial. J Clin Oncol 35:1041–1048

    Article  CAS  PubMed  Google Scholar 

  • Smith MR, Egerdie B, Hernández Toriz N et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745–755

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Smith MR, McGovern FJ, Zietman AL et al (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345:948–955

    Article  CAS  PubMed  Google Scholar 

  • Souchon R, Wenz F, Sedlmayer F et al (2009) DEGRO practice guidelines for palliative radiotherapy of metastatic breast cancer: bone metastases and metastatic spinal cord compression (MSCC). Strahlenther Onkol 185(7):417–424

    Article  PubMed  Google Scholar 

  • Stopeck AT, Fizazi K, Body JJ et al (2016) Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 24:447–455

    Article  PubMed  Google Scholar 

  • Stopeck AT, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139

    Article  CAS  PubMed  Google Scholar 

  • Sverrisdóttir A, Fornander T, Jacobsson H et al (2004) Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 22:3694–3699

    Article  PubMed  Google Scholar 

  • Taylor LG, Canfield SE, Du XL (2009) Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115:2388–2399

    Article  PubMed  Google Scholar 

  • Tokuhashi Y, Uei H, Oshima M et al (2014) Scoring system for prediction of metastatic spine tumor prognosis. World J Orthop 5(3):262–271

    Article  PubMed  PubMed Central  Google Scholar 

  • Tokuhashi Y et al (1990) Scoring system for the preoperative evaluation of the metastatic spine tumor prognosis. Spine 15:1110–1113

    Article  CAS  PubMed  Google Scholar 

  • Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T (2001) Surgical strategy for spinal metastases. Spine 26:298–306

    Article  CAS  PubMed  Google Scholar 

  • Tong D, Gillick L, Hendrickson FR (1982) The palliation of symptomatic osseous metastases: final results of the study by the radiation oncology group. Cancer 50:893–899

    Article  CAS  PubMed  Google Scholar 

  • Vadhan-Raj S, von Moos R, Fallowfield LJ et al (2012) Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol 23:3045–3051

    Article  CAS  PubMed  Google Scholar 

  • Van Poznak C, Hannon RA, Mackey JR et al (2010) Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 28:967–975

    Article  PubMed  CAS  Google Scholar 

  • Wardley A, Davidson N, Barrett-Lee P et al (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised crossover study of community vs. hospital bisphosphonate administration. Br J Cancer 92:1869–1876

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wedin R, Bauer HC, Rutqvist LE (2001) Surgical treatment for skeletal breast cancer metastases: a population-based study of 641 patients. Cancer 92(2):257–262

    Article  CAS  PubMed  Google Scholar 

  • Weinfurt KP, Li Y, Castel LD et al (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16:579–584

    Article  CAS  PubMed  Google Scholar 

  • Wenz F, Schneider F, Neumaier C, Kraus-Tiefenbacher U, Reis T, Schmidt R et al (2010) Kypho-IORT – a novel approach of intraoperative radiotherapy during kyphoplasty for vertebral metastases. Radiation Oncol 5:11

    Article  Google Scholar 

  • Wong E, Hoskin P, Bedard G et al (2014) Re-irradiation for painful bone metastases – a systematic review. Radiother Oncol 110:61–70

    Article  PubMed  Google Scholar 

  • Zheng Y, Zhou H, Brennan K et al (2007) Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 40:471–478

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gynäkologischer Onkologe, Osteoonkologe Praxisklinik am Rosengarten, Mannheim, Deutschland

    Ingo J. Diel

  2. Ltd Oberarzt/Hämatologie, Onkologie und Stammzelltransplantation, Asklepios Klinik St. Georg, Hamburg, Deutschland

    Christian-Friedrich Jehn

  3. Endokrinologie, Diabetes und Knochenstoffwechselerkrankungen, Uniklinikum Gustav Carus Dresden, Dresden, Deutschland

    Tilman D. Rachner

Authors
  1. Ingo J. Diel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian-Friedrich Jehn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tilman D. Rachner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ingo J. Diel .

Editor information

Editors and Affiliations

  1. Abt. Hämatologie und Onkologie, Universitätsklinikum Halle-Wittenberg Klinik und Poliklinik Innere Medizin IV, Halle, Sachsen-Anhalt, Deutschland

    Hans-Joachim Schmoll

Section Editor information

  1. Klinik und Poliklinik für Radiologie, Medizinische Fakultät Ludwig-Maximilians-Universität München, München, Deutschland

    Jens Ricke

  2. Klinik für Radiologie, Charité, Campus Virchow-Klinikum, Berlin, Deutschland

    Bernhard Gebauer

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Diel, I.J., Jehn, CF., Rachner, T.D. (2022). Osteoonkologie: Knochenmetastasen und Tumortherapie-induzierte Osteoporose. In: Schmoll, HJ. (eds) Kompendium Internistische Onkologie . Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46764-0_195-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-46764-0_195-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-46764-0

  • Online ISBN: 978-3-662-46764-0

  • eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics

Search

Navigation